resistant hypertension
Conditions
Interventions
Sponsors
Department of Cardiology, the First Affiliated Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Sign and date any procedures prescribed by the study; 2.Male and female subjects; 3.Aged 18 years or above; 4.In the subject's medical records, there were clear medical records of at least 3 background antihypertensive medications received within 1 year prior to the screening visit but not controlled by blood pressure.Treated with at least 3 different pharmacological classes of antihypertensive drugs (including diuretics) for at least 4 weeks prior to screening. ß receptor blockers are not considered background antihypertensive drugs. 5.The average SiSBP measured by AOBP during screening visits was >=140mmHg. Or there is a clear record of a diagnosis of RHT in the subject's medical records; Or after switching from background antihypertensive drugs (i.e., at least 3 different pharmacological classes of drugs, including diuretics) to standardized background antihypertensive therapy, the mean valley value of SiSBP measured by AOBPM >=140mmHg; Or switch to standardized background antihypertensive therapy at least 4 weeks before the first RI visit, with an AOBPM measured SiSBP trough >=140mmHg.
Exclusion criteria
Exclusion criteria: 1.Subjects who are pregnant or nursing; 2.Epigenetic/False RHT due to white coat effect, medical inertia, poor treatment compliance, or secondary causes of hypertension (excluding obstructive sleep apnea); 3.Confirmed severe hypertension (grade 3); transient cerebral ischemic seizures, strokes, unstable angina or myocardial infarction (MI) are known and recorded within 6 months of screening; 4.Researchers believe there is clinically significant unstable heart disease, such as uncontrolled symptomatic arrhythmia, atrial fibrillation, NYHAIII or IV-grade congestive heart failure; 5.Severe renal insufficiency was defined as eGFR<15mL/min/1.73m^2 estimated using CKD epidemiology and creatinine equation; Type 1 DM; 6.The researchers believe that subjects may be put at risk, interfere with treatment compliance, study execution, or interpretation of any known factors, diseases, or clinically relevant internal or surgical conditions; 7.Any medication (e.g. psychiatric medication) that may affect BP.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean blood pressure (SBP) in the clinic from baseline to week 16 of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in 24-hour mean SPB and DBP of ambulate blood pressure from baseline to week 12 of treatment;Mean SBP changes from baseline to week 12 in the clinic;Incidence of major adverse cardiovascular events, heart failure, malignant arrhythmias, and coronary events after percutaneous coronary intervention;Incidence of acute myocardial infarction; | — |
Countries
China
Contacts
Public ContactLi Zhao
The First Affiliated Hospital of China Medical University
Outcome results
None listed